{
    "clinical_study": {
        "@rank": "112550", 
        "arm_group": {
            "arm_group_label": "Recombinant Factor VIII", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Comparison of the effect of three times a week prophylaxis on all bleeds with on-demand\n      treatment for children with severe Hemophilia A."
        }, 
        "brief_title": "Prophylaxis Versus on Demand Treatment for Children With Hemophilia A", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, aged 2-16yrs\n\n          -  Severe hemophilia A (<1% FVIII:C [Blood Clotting Factor VIII:C] )\n\n          -  Minimum of at least 50 documented ED (exposure day) prior to enrolment\n\n          -  No measurable inhibitor activity at baseline and history of FVIII inhibitor antibody\n             formation\n\n          -  Parents or legal guardians document, sign, and date informed consent\n\n        Exclusion Criteria:\n\n          -  Another bleeding disease that is different from hemophilia A\n\n          -  Known hypersensitivity to the active substance, mouse or hamster protein\n\n          -  Thrombocytopenia (platelet count <100 000/mm3) based on previous medical records"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810666", 
            "org_study_id": "16287", 
            "secondary_id": "2014-001362-10"
        }, 
        "intervention": {
            "arm_group_label": "Recombinant Factor VIII", 
            "description": "On-demand treatment phase for 12 weeks will be followed by 12 weeks prophylaxis treatment phase. The dose in on-demand treatment will be decided by physician according to the package insert or the current standard of care. The dose and mode of prophylaxis treatment will be 25 IU/Kg, 3 times/per week.", 
            "intervention_name": "Recombinant Factor VIII (Kogenate FS, BAY14-2222)", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 31, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510515"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430022"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100730"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Routine Prophylaxis Treatment Versus On-demand Treatment for Children With Severe Hemophilia A: Comparison of All Bleeding Events in Chinese Hemophilia Patients", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of bleeds during on-demand and prophylaxis treatment periods", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810666"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of joint bleeds during on-demand and prophylaxis treatment periods", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "measure": "Joint function assessed by the Hemophilia Joint Health Score", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}